Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.
Also called NCT02851745
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 188 participants
- Sponsor
- Heart Care Foundation
- Registry
-
NCT02851745
-
- Main results
- Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT02851745. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2019-07-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
- Acronym
- DYDA2
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Left Ventricular Systolic Dysfunction
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Heart Care Foundation
- Collaborator
- Fondazione dell'Associazione Medici Diabetologi
Record details
- Record id
cardio:ct-nct02851745- Content hash
d7d911a47c843ec85465184701b71db80f2283aa702ef674214d259bb88ecdcd